The Importance of Patient Health-Related Quality of Life – EORTC
European Organisation for Research and Treatment of Cancer (EORTC) shared a post on LinkedIn:
“New policy review in The Lancet Group Oncology.
A collaborative effort by Ian Tannock, Madeline Pe, the European Organisation for Research and Treatment of Cancer (EORTC), and Common Sense Oncology (CSO) stresses the critical importance of patient health-related quality of life (HRQoL) data in advanced cancer trials.
Key insights:
- HRQoL should be at least a key secondary outcome, alongside traditional clinical endpoints like overall survival
- Standardised responder criteria make HRQoL data more meaningful for patients & clinicians
- Patients must be actively involved in trial design
- Clear HRQoL reporting enables better clinical decision-making
“Our goal is to ensure the benefits of cancer treatments are fully understood, not only in terms of survival, but also how they impact patients’ daily lives.” – Prof. Ian F. Tannock, co-lead author of the paper.
Read more and access the full publication.”
More posts featuring European Organisation for Research and Treatment of Cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023